This pediatric clinical trial aims to test the safety, tolerability and immunogenicity of Pfizer’s COVID vaccine in children under 12 years of age
Obtain the necessary information to complete the technical data sheet of these vaccines and to have all the safety rigour on how they work so that, if necessary, the paediatric population can be vaccinated with the same guarantees as adults.”
Description of Study:
- Title: Pediatric clinical trial of Pfizer’s COVID vaccine in children under 12 years of age.
- Principal Investigador: Federico Martinón Torres.
- Centres of implementation: Global clinical trial involving the Hospital Clínico Universitario de Santiago.
- Study population: Children under 12 years of age will participate. The clinical trial at the Hospital Clínico Universitario de Santiago will involve 55 healthy children who will take part in the global study, which is expected to include 4,644 young people, 557 of them in Spain.
- Type of study: Double-blind clinical trial.
- Methods: Participants will receive an injection approximately 3 weeks apart and those receiving placebo (one third) will have the opportunity to receive the vaccine within the study. Follow-up visits are scheduled and there will be a two-year follow-up period for each child.
Objectives of the Study:
Principal Objective: To evaluate the safety, tolerability and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in the prevention of COVID-19 in healthy children under 12 years of age.
More about this Study:
The Complejo Hospitalario Universitario de Santiago de Compostela belongs to the Galician network of public use of the Galician Health Service and brings together the four hospitals located in Santiago de Compostela: Hospital Clínico Universitario, Hospital Médico Quirúrgico de Conxo, Hospital Gil Casares and Hospital Psiquiátrico de Conxo.
Other Clinical Trials:
Clinical trial designed to evaluate the safety and immunogenicity of a dose of Comirnaty vaccine (Pfizer) in people who have previously received a dose of Vaxcevria vaccine (AstraZeneca).
This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.
Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 disease may slow disease progression and decrease the severity of symptoms.
Using a mouthwash containing β-cyclodextrin and citrox (bioflavonoids) (CDCM), available in pharmacies, helps reduce the SARS-CoV-2 viral load in saliva.
The LacCOVID study has shown that milk from lactating women who have been vaccinated with Pfizer-BioNTech contains specific antibodies against the SARS-CoV-2 coronavirus.
Clinical trial to perform immunomodulatory treatment in adult patients with severe COVID-19 pneumonia with the aim of helping to define the standard treatment for this disease.
This multicentre clinical trial aims to demonstrate that treatment with Calcifediol reduces the need for invasive ventilation and Intensive Care Unit admissions and deaths.
Phase II clinical trial evaluating the safety and efficacy of the drug Maraviroc combined with standard therapy versus standard therapy in patients infected with SARS-CoV-2 and hospitalised with COVID-19.